Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.

American Journal of Clinical Oncology
Alan H BryceJames R Jett

Abstract

The objective of this study was to evaluate the response rate and toxicities of the combination of oral topotecan and carboplatin in patients with untreated extensive stage small cell lung cancer (ES-SCLC). Previous studies have suggested improved outcomes with a topoisomerase I inhibitor in combination with a platinum agent. Twenty-six patients with previously untreated, ES-SCLC were evaluable in this phase II trial. All patients received oral topotecan 2.0 mg/m per day on days 1 through 5 and carboplatin at an area under curve of 5 on day 5. Treatment was repeated every 21 days up to a total of 6 cycles. All patients received G-CSF. There were no complete responses and 16 partial responses, for an overall response rate of 62% (95% CI: 41-80). Median time to progression was 6.0 months (95% CI: 4-8), with a median overall survival of 12 months (95% CI: 8-16). This study was closed to accrual early with 26 of a planned 39 patients enrolled because of grade 5 adverse events in 4 (15%) patients (3 neutropenic infections, 1 sudden cardiac death). Eighty-five percent of patients experienced grade 3 or higher hematologic events. The most common severe nonhematologic events included diarrhea, vomiting, dyspnea, hypoxia, and hypotensio...Continue Reading

References

Apr 1, 1984·International Journal of Radiation Oncology, Biology, Physics·G MorstynJ D Minna
Sep 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D V SkarlosG Klouvas
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A W MaksymiukM Wiesenfeld
Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H SchillerD Johnson
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J de JongeJ Verweij
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J von PawelG Ross
Jan 11, 2002·The New England Journal of Medicine·Kazumasa NodaUNKNOWN Japan Clinical Oncology Group
Feb 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S RamalingamJ R Jett
Oct 9, 2004·The Journal of Biological Chemistry·Robert C A M van WaardenburgJan H M Schellens
May 2, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaAlan Sandler
Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·F VecchioneA A Lissoni
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nevin Murray, Andrew T Turrisi
Oct 9, 2007·Cancer Chemotherapy and Pharmacology·Dominique KoensgenUNKNOWN North-Eastern German Society of Gynecological Oncology Study Group-Ovarian Cancer
Nov 27, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Morten SorensenSeppo W Langer
Aug 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Morten SorensenSeppo Wang Langer

❮ Previous
Next ❯

Citations

Feb 14, 2015·British Journal of Clinical Pharmacology·Lot A DevrieseJan H M Schellens

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A BowmanJ F Smyth
Japanese Journal of Clinical Oncology
Yukito IchinoseKoshiro Watanabe
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Paul J HeskethD R Gandara
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
David R SpigelF Anthony Greco
© 2022 Meta ULC. All rights reserved